AUSTRALIANS diagnosed with ROS1-positive non-small cell lung cancer (NSCLC) now have subsidised access to a new targeted treatment, Augtyro (repotrectinib, BMS Australia), through the Pharmaceutical Benefits Scheme (PBS).
ROS1-positive NSCLC is a rare subset affecting only 1-2% of NSCLC patients, and compared to others with NSCLC people with ROS1 rearrangements, are younger and more likely to have never smoked.
The listing also highlights the growing role of molecular testing in lung cancer care, where identifying the specific genetic features of a person's cancer allows clinicians to personalise treatment, rather than take a one-size-fits-all approach.
"We welcome the PBS listing of Augtyro as an additional treatment option for people with ROS1-positive NSCLC," said Paige Preston from Lung Foundation Australia.
"For those affected by rare cancers, timely access to publicly funded treatments is especially important so that these communities are not left behind," she added.
BMS ANZ GM Owen Smith said the PBS listing of Augtyro was an important milestone for the company and underscores its commitment to people living with rare lung cancer.
The above article was sent to subscribers in Pharmacy Daily's issue from 17 Apr 26
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 17 Apr 26
